Q1 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Innovation: Pipeline overview
Appendix
Innovation: Clinical trials
References
Abbreviations
Key milestones of pipeline assets with significant sales potential
with approval by 2026
Selected assets, most advanced and key indication(s) approved by 2026
High strength of evidence
Iptacopan PNH
Iptacopan C3G
Iptacopan aHUS
Iptacopan IgAn
Remibrutinib CSU
2022
Ph3 readout
2023
Submission
2024
2025
2026
High strength of evidence
Ensovibep Coronavirus infection
2022
Submission
2023
2024
2025
2026
Ph3 read/sub
Scemblix
Approval
Scemblix CML 1L
Ph3 readout
Submission
Ph3 readout Submission
Vijoice PROS
Approval
Ph3 read/sub
Piqray Ovarian Cancer
Ph3 read/sub
Ph3 read/sub
Piqray TNBC
Ph3 read/sub
Ph3 read/sub
Piqray HER2+ adv BC
Ph3 read/sub
Ph3 readout
Submission
Tislelizumab
Submissions and approvals of several indications
Ph3 read/sub
Remibrutinib MS
Zolgensma SMA IT
Ligelizumab Food Allergy
Kisqali
Ph3 read/sub
YTB323 2L DLBCL
Ph3 start
lanalumab Sjögren's
Ph3 start
lanalumab LN
Ph3 start
Cosentyx HS
Cosentyx Lichen Planus
Cosentyx GCA
Pluvicto mCRPCR post taxane
Pluvicto mCRPCR pre taxane
Pluvicto tetraxetan mHSPC
NME Lead
1. Event driven, could move to early 2023.
36 Investor Relations | Q1 2022 Results
Moderate strength of evidence
Ph3 read/sub
Sabatolimab MDS
2022
Ph2 readout
2023
2024
2025
2026
Ph3 read/sub
Sabatolimab AML
Ph3 readout
Ph3 readout
Submission in 2022/23
Submission
Ph3 read/sub
NIS793 PDAC
Ph3 read/sub
Submission
Ph2 readout
Pelacarsen CVRR
Ph3 read/sub
Submission
Ph3 read/sub
Canakinumab Adj. NSCLC
Ph3 readout
Submission
Ociperlimab
Approved
UNR844 Presbyopia
Ph3 start
Ph2 readout
BeiGene option deal
Submission
Ph3 readout¹ Submission
Ph3 read/sub
Libvatrep COSP
Ph2 readout
Submission
JDQ443 NSCLC
JDQ443+TNO155 NSCLC
Ph3 start
Submission
Ph3 start
Submission
✓ NOVARTIS | Reimagining MedicineView entire presentation